132 related articles for article (PubMed ID: 18598778)
1. Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent.
Huskens D; Vermeire K; Vandemeulebroucke E; Balzarini J; Schols D
Int J Biochem Cell Biol; 2008; 40(12):2802-14. PubMed ID: 18598778
[TBL] [Abstract][Full Text] [Related]
2. The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1.
Huskens D; Vermeire K; Profy AT; Schols D
Antiviral Res; 2009 Oct; 84(1):38-47. PubMed ID: 19664662
[TBL] [Abstract][Full Text] [Related]
3. Sugar-binding proteins potently inhibit dendritic cell human immunodeficiency virus type 1 (HIV-1) infection and dendritic-cell-directed HIV-1 transfer.
Turville SG; Vermeire K; Balzarini J; Schols D
J Virol; 2005 Nov; 79(21):13519-27. PubMed ID: 16227272
[TBL] [Abstract][Full Text] [Related]
4. Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models.
Buffa V; Stieh D; Mamhood N; Hu Q; Fletcher P; Shattock RJ
J Gen Virol; 2009 Jan; 90(Pt 1):234-43. PubMed ID: 19088294
[TBL] [Abstract][Full Text] [Related]
5. Properties of cyanovirin-N (CV-N): inactivation of HIV-1 by sessile cyanovirin-N (sCV-N).
Gandhi MJ; Boyd MR; Yi L; Yang GG; Vyas GN
Dev Biol (Basel); 2000; 102():141-8. PubMed ID: 10794101
[TBL] [Abstract][Full Text] [Related]
6. Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes.
Balzarini J; Van Laethem K; Peumans WJ; Van Damme EJ; Bolmstedt A; Gago F; Schols D
J Virol; 2006 Sep; 80(17):8411-21. PubMed ID: 16912292
[TBL] [Abstract][Full Text] [Related]
7. Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile.
Huskens D; Férir G; Vermeire K; Kehr JC; Balzarini J; Dittmann E; Schols D
J Biol Chem; 2010 Aug; 285(32):24845-54. PubMed ID: 20507987
[TBL] [Abstract][Full Text] [Related]
8. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition.
Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM
Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344
[TBL] [Abstract][Full Text] [Related]
9. Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development.
Colleluori DM; Tien D; Kang F; Pagliei T; Kuss R; McCormick T; Watson K; McFadden K; Chaiken I; Buckheit RW; Romano JW
Protein Expr Purif; 2005 Feb; 39(2):229-36. PubMed ID: 15642474
[TBL] [Abstract][Full Text] [Related]
10. PEGylation of cyanovirin-N, an entry inhibitor of HIV.
Zappe H; Snell ME; Bossard MJ
Adv Drug Deliv Rev; 2008 Jan; 60(1):79-87. PubMed ID: 17884238
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a stable dimeric mutant of cyanovirin-N (CV-N) from a T7 phage-displayed CV-N mutant library.
Han Z; Xiong C; Mori T; Boyd MR
Biochem Biophys Res Commun; 2002 Apr; 292(4):1036-43. PubMed ID: 11944919
[TBL] [Abstract][Full Text] [Related]
12. Flipping the switch from monomeric to dimeric CV-N has little effect on antiviral activity.
Barrientos LG; Lasala F; Delgado R; Sanchez A; Gronenborn AM
Structure; 2004 Oct; 12(10):1799-807. PubMed ID: 15458629
[TBL] [Abstract][Full Text] [Related]
13. Transgenic plant production of Cyanovirin-N, an HIV microbicide.
Sexton A; Drake PM; Mahmood N; Harman SJ; Shattock RJ; Ma JK
FASEB J; 2006 Feb; 20(2):356-8. PubMed ID: 16354721
[TBL] [Abstract][Full Text] [Related]
14. The antiviral protein cyanovirin-N: the current state of its production and applications.
Xiong S; Fan J; Kitazato K
Appl Microbiol Biotechnol; 2010 Apr; 86(3):805-12. PubMed ID: 20162270
[TBL] [Abstract][Full Text] [Related]
15. Atomic mapping of the interactions between the antiviral agent cyanovirin-N and oligomannosides by saturation-transfer difference NMR.
Sandström C; Berteau O; Gemma E; Oscarson S; Kenne L; Gronenborn AM
Biochemistry; 2004 Nov; 43(44):13926-31. PubMed ID: 15518540
[TBL] [Abstract][Full Text] [Related]
16. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N.
Liu X; Lagenaur LA; Simpson DA; Essenmacher KP; Frazier-Parker CL; Liu Y; Tsai D; Rao SS; Hamer DH; Parks TP; Lee PP; Xu Q
Antimicrob Agents Chemother; 2006 Oct; 50(10):3250-9. PubMed ID: 17005802
[TBL] [Abstract][Full Text] [Related]
17. Interferon-gamma-mediated pathways and in vitro PBMC proliferation in HIV-infected patients.
Schroecksnadel K; Winkler C; Werner ER; Sarcletti M; Romani N; Ebner S; Schennach H; Fuchs D; Zangerle R
Biol Chem; 2009 Feb; 390(2):115-23. PubMed ID: 19040353
[TBL] [Abstract][Full Text] [Related]
18. The highly specific carbohydrate-binding protein cyanovirin-N: structure, anti-HIV/Ebola activity and possibilities for therapy.
Barrientos LG; Gronenborn AM
Mini Rev Med Chem; 2005 Jan; 5(1):21-31. PubMed ID: 15638789
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of transmitted and founder human immunodeficiency virus type 1 envelopes to carbohydrate-binding agents griffithsin, cyanovirin-N and Galanthus nivalis agglutinin.
Hu B; Du T; Li C; Luo S; Liu Y; Huang X; Hu Q
J Gen Virol; 2015 Dec; 96(12):3660-3666. PubMed ID: 26407826
[TBL] [Abstract][Full Text] [Related]
20. Correlation between the degree of immune activation, production of IL-2 and FOXP3 expression in CD4+CD25+ T regulatory cells in HIV-1 infected persons under HAART.
Terzieva V; Popova D; Kicheva M; Todorova Y; Markova R; Martinova F; Elenkov I; Yankova M
Int Immunopharmacol; 2009 Jul; 9(7-8):831-6. PubMed ID: 19303058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
